Latest Articles

Publication Date
Genetically predicted triglyceride levels and endometriosis risk: Mendelian randomization with exploratory multi-omics analyses.

This study explored the genetic evidence linking triglyceride-related pathways and lipid-lowering drug targets with endometriosis risk and investigated the genetic association between TG levels and EM. Using genome-wide association study …

Published: Aug. 13, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
Activin A is a functional component of the anti-endometriotic drug Endoferin.

Endometriosis is a prevalent gynecological condition affecting up to 25-40% of women with infertility. Endoferin, a protein complex derived from the bovine ovarian follicles, has demonstrated high efficacy in clinical …

Published: July 31, 2026, midnight
NLRP3/Caspase-1-Mediated Pyroptosis Drives a Brain-Lesion Neuroimmune Axis in Endometriosis-Associated Pain: Molecular Mechanisms and Transcranial Direct Current Stimulation Intervention.

Background/Objectives: The NLRP3 inflammasome-Caspase-1-IL-1β pyroptotic axis participates in peripheral inflammatory responses, yet its function in peripheral-central neuroimmune crosstalk underlying endometriosis (EM)-associated pain remains unclear. This study aimed to clarify whether …

Published: July 30, 2026, midnight
Glycolytic Reprogramming in Endometriosis: Biological Basis and Emerging Targets for Disease-Modifying Therapy.

Endometriosis is a chronic gynecological disease affecting approximately 10% of women of reproductive age and up to 40% of women with infertility, with a significant impact on quality of life …

Published: July 23, 2026, midnight
Rheumatic Heart Disease: Inflammation, Immune Pathways, Valve Remodeling, and the Promise of SGLT2 Inhibitors.

Rheumatic heart disease (RHD) remains the leading cause of acquired valvular heart disease in low- and middle-income countries, affecting an estimated 40 million individuals and disproportionately affecting children and young …

Published: July 16, 2026, midnight
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
PGRMC1 suppression enhances progesterone responsiveness in stromal cells of ovarian endometrioma.

Progesterone resistance in endometriosis reduces the efficacy of progestin. The non-classical progesterone receptor, progesterone receptor membrane component 1 (PGRMC1) may regulate progesterone signaling in the normal endometrium, but its expression …

Published: July 6, 2026, midnight
Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may …

Published: July 3, 2026, midnight
Analysis of Drug Clinical Trials in Obstetrics and Gynecology: A Five-Year Retrospective Study from a Public Tertiary Specialty Hospital in China.

Women remain underrepresented in clinical drug development despite their unique biological characteristics and growing disease burden. In China, this disparity is particularly concerning given the rising incidence of gynecologic conditions …

Published: June 30, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!